Eight hundred forty-four patients underwent HSCT at the Hospital for Sick Children, Toronto, Canada during the study period and comprise the study population. The transplant recipients consisted of 341 female and 503 male patients, with a median age of 7.5 years (range, 1 month to 17.8 years). The HSCT was allogeneic in 491 patients and autologous in 353 patients. The diseases for which HSCT was performed were acute lymphoblastic leukemia (n ¼ 138), acute myeloid leukemia (n ¼ 110), myelodysplastic syndrome (n ¼ 21), severe aplastic anemia (n ¼ 49), inherited marrow failure (n ¼ 29), primary immune deficiency (n ¼ 58), non-Hodgkin lymphoma (n ¼ 44), Hodgkin disease (n ¼ 28), chronic myelogenous leukemia (n ¼ 16), metabolic diseases (n ¼ 25), hemophagocytic lymphohistiocytosis (n ¼ 17), brain tumors (n ¼ 103), solid tumors (n ¼ 179), thalassemia (n ¼ 15), and others (n ¼ 12). 